A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderatley severe active Crohn's disease

JC Mansfield, M Parkes, AB Hawthorne, A Forbes, C Probert, RC Perowne, A Cooper, JB Zeldis, DC Manning, CJ Hawkey

Research output: Contribution to journalArticle (Academic Journal)peer-review

Abstract

BACKGROUND: Therapy targeted at tumour necrosis factor-alpha has an established role in Crohn's disease. Lenalidomide, an analogue of thalidomide, is an oral immunomodulatory agent with powerful antitumour necrosis factor-alpha properties. It is licensed for myeloma and myelodysplastic syndrome. Based upon reports of thalidomide efficacy, lenalidomide was evaluated in Crohn's disease. AIM: To evaluate the efficacy and safety of lenalidomide in subjects with moderately severe active Crohn's disease. METHODS: In a multicentre, double-blind, placebo-controlled parallel group study 89 subjects were randomized to lenalidomide 25 mg daily, 5 mg daily or placebo. Subjects were treated for 12 weeks. The primary end point was a 70-point reduction in Crohn's Disease Activity Index. RESULTS: The overall clinical response rate was not significantly different between the three groups: lenalidomide 25 mg 26%, lenalidomide 5 mg 48% and placebo 39%. Lenalidomide was generally well tolerated with only one serious adverse event, a deep vein thrombosis, being attributed to treatment. CONCLUSION: Lenalidomide, an oral agent with antitumour necrosis factor-alpha properties, was not effective in active Crohn's disease in contrast to reports of benefit from thalidomide. The reasons for this lack of efficacy are speculative, other physiological activities may offset its action on inflammatory cytokines, or its antitumour necrosis factor-alpha action without apoptosis may be insufficient for activity in Crohn's disease.
Translated title of the contributionA randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderatley severe active Crohn's disease
Original languageEnglish
Pages (from-to)421 - 430
Number of pages10
JournalAliment Pharmacol Ther
Volume1;26(3)
Publication statusPublished - Aug 2007

Fingerprint Dive into the research topics of 'A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderatley severe active Crohn's disease'. Together they form a unique fingerprint.

Cite this